More News! 4 Feb 2017 This PhD-Carrying Musician Tells the Story of Life through Music & Video Max Cooper bridges the age-old divide between science and art with a transfixing blend of glitchy electronica, classical music and haunting vocals. I was lucky enough to catch Max Cooper live in Dublin last weekend, during his tour to showcase his latest album, Emergence. Inspired by natural processes and the laws underlying them, Emergence is a tour-de-force of […] February 4, 2017 - 6 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 3 Feb 2017 Could GM Insects impact the international trade of Organic Food? Genetically modified insects are released to control the spread of diseases and crop pests, but the logistics may not be so simple: these little creatures could jam global food exports, particularly to more GM-averse Europe. What happens when genetically engineered insects develop on vegetable farms? Two researchers, from the Max Planck Institue for Evolutionary Biology in […] February 3, 2017 - 3 minutesmins - By Denise Neves Gameiro Share WhatsApp Twitter Linkedin Email
More News! 2 Feb 2017 Galapagos kicks off a Phase IIa trial for Cystic Fibrosis After Galapagos and AbbVie expanded their collaboration on cystic fibrosis, Galapagos now announces the start of their Phase IIa trial for a novel cystic fibrosis corrector. Since entering their collaboration with AbbVie on cystic fibrosis (CF) in 2013, Galapagos has received almost €40M in milestone payments from AbbVie. Galapagos now announced the start of a Phase […] February 2, 2017 - 2 minutesmins - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email
News and Trends 1 Feb 2017 Young Belgian Biotech will tackle Fibrosis with a New Grant Confo Therapeutics has received a €1.6M grant to support the discovery of drugs against fibrosis, one of the most deadly conditions in Western countries. Confo Therapeutics is a young biotech in Brussels developing a unique technology to target historically undruggable G protein-coupled receptors (GPCRs). The company just announced it received a €1.6M grant from Flanders Innovation & […] February 1, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 1 Feb 2017 Meet these 3 Exciting German Startups Pitching in Aachen Today! Today is Life Science Pitch Day in Aachen! High-Tech Gründerfonds has invited a handful of startups in the seed and Series A stages to make their pitches to investors this afternoon. Here are three of the companies who you’ll hear speak! cytena cytena, a spinoff from the University of Freiburg, is improving current methods in […] February 1, 2017 - 3 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 1 Feb 2017 Young German Immune Therapy Biotech expands its Series A Funding Immunic Therapeutics has received an extra €4M that will be directed at speeding the development of treatments for Crohn’s disease and psoriasis. Immunic Therapeutics is a young company based in Munich’s biotech hub that develops immune therapies for chronic inflammatory diseases. Today, it announced a €4M investment from IBG, which increases its Series A financing to a […] February 1, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 1 Feb 2017 Stem Cell Therapy for Sepsis in Pneumonia advances to Phase II TiGenix has treated the first patient in a new early-stage clinical trial to test its candidate Cx611 as a treatment for sepsis in patients with pneumonia. TiGenix, based in Belgium, develops stem cell therapies derived from donors. This morning, the first patient was treated in a Phase Ib/IIa clinical trial for its candidate therapy Cx611 in […] February 1, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 31 Jan 2017 New British Biotech-Academia Alliance takes on Cardiovascular Disease Heptares Therapeutics and the University of Cambridge have partnered to investigate a novel target for cardiovascular diseases. Heptares Therapeutics, based in London, develops drugs against historically undruggable G protein-coupled receptors (GPCRs). The company has now announced a new research collaboration with the University of Cambridge focusing on a specific GPCR, the apelin receptor. Heptares will support a […] January 31, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 31 Jan 2017 Top 5 Biologicals from European Biopharma to Launch in 2017 A new report listing the top drug launches this year reveals the strong performance of biologicals and European biopharma on the drug market. After the worst year in biotech finance, experts seem to agree that the industry will start recovering in 2017. There are still substantial uncertainties, mostly regarding the new US administration. Though a […] January 31, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
In Depth 31 Jan 2017 Biologicals on the Brain: Biotech in Neurodegenerative Disease Brain diseases are hard to treat, but biotechs are harnessing a variety of techniques, including immunotherapy and gene therapy, to target neurodegenerative disorders. When Eli Lilly announced that solanezumab, a long anticipated Alzheimer’s antibody, failed in their third attempt at a late stage trial last year, it crushed patients’ hopes and raised doubts about whether […] January 31, 2017 - 7 minutesmins - By Diana Kwon Share WhatsApp Twitter Linkedin Email
News and Trends 30 Jan 2017 Novo Nordisk will open a €135M Diabetes R&D Center at Oxford University A new research center funded by Novo Nordisk will foster collaborations between its staff and researchers from the University of Oxford. Novo Nordisk and the University of Oxford have announced a collaboration focused on type 2 diabetes research. As part of the effort, the Danish pharma will invest €135M (£115M) over a 10-year period to […] January 30, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 30 Jan 2017 The FDA gives Fast Track Priority to uniQure’s Hemophilia B Gene Therapy UniQure has received Breakthrough Therapy Designation from the FDA, granting fast track to its gene therapy for hemophilia B. UniQure is one of the companies leading the development of gene therapy for hemophilia. Now, the FDA has granted Breakthrough Therapy Designation to its candidate AMT-060 for hemophilia B. This is awarded to selected therapies that have […] January 30, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email